天茂集團(000627.SZ):成功申購國華人壽2021年第一期資本補充債券2.4億元
格隆匯7月8日丨天茂集團(000627.SZ)公佈,經中國銀行保險監督管理委員會和中國人民銀行批准,國華人壽於2021年7月6日在銀行間債券市場成功發行“國華人壽保險股份有限公司2021年第一期資本補充債券”,並於2021年7月8日發行完畢。
本期債券發行總規模為人民幣30億元,品種為10年期固定利率債券,票面利率為5.5%,在第5年末附有條件的發行人贖回權。本期債券募集資金將依據適用法律和監管部門的批准,用於補充國華人壽資本以提高償付能力。
公司通過中海信託股份有限公司作為受託管理人的“中海-銀葉穩健5號單一資金信託”在銀行間債券市場成功申購國華人壽保險股份有限公司2021年第一期資本補充債券2.4億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.